More Business Wire
View Older Stories View Newer Stories-
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
-
Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2024 Annual Meeting
-
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
-
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
-
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
-
Barnes & Noble Education Announces Preliminary Fiscal Year 2024 Results
-
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel
-
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
-
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
-
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
-
TelevisaUnivision Announces Pricing of $1.0 Billion Debt
-
BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Declares Distribution
-
KBRA Assigns AAA Rating, Stable Outlook to the New Mexico Finance Authority State Transportation Revenue Refunding Bonds (State Transportation Commission - Senior Lien), Series 2024A
-
Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program
-
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First
-
NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data using Mismatched, Unrelated Donors at 2024 ASCO Annual Meeting
-
Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
-
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
-
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
-
Orca Bio to Present Positive Clinical Outcomes with Orca-T in Patients with AML at 2024 ASCO Annual Meeting
-
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
-
City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Comvest Partners Announces $70 Million Senior Credit Facility For Nationwide Energy Partners to Support Growth Strategy
-
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
-
NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Socie
-
AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer
-
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
-
Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual Meeting
-
Klaviyo to Present at the William Blair Growth Stock Conference
-
Dentalcorp Announces Annual General Meeting Voting Results
-
Ligand to Participate in Upcoming Investor Conferences
-
Genworth Financial Announces Results of Annual Meeting
-
Phreesia’s Amy Patel Named One of PM360’s 2024 ELITE 100
-
Alerus Financial Corporation Declares Cash Dividend on Common Shares
-
Enhabit Provides Additional Details on Robust Strategic Review Process
-
Lincoln National Corporation's Board of Directors Declares Quarterly Cash Dividend
-
Caleres Declares Regular Quarterly Dividend
-
Stevanato Group to Present at Upcoming Investor Conferences
-
Sallie Mae CFO to Speak at TD Financial Services & Fintech Summit
-
Secret Creek Fish Passage Project Nets Granite $48 Million Contract in Snohomish County, Washington
-
Hecla Announces Leadership Transition
-
On Elects Laura Miele as a New Independent Member of the Board of Directors
-
Terra and Grass River Awarded WiredScore Platinum Certification with a Smart Home Designation at Grove Central in Miami, FL
-
AM Best Downgrades Issuer Credit Ratings of Lumico Life Insurance Group Members; Places Credit Ratings Under Review With Negative Implications
-
SatixFy Announces First Quarter 2024 Results
-
ProAssurance Announces Election of Richard J. Bielen, C.P.A., and Staci M. Pierce, J.D., to Board
-
AM Best Places Credit Ratings of iptiQ Life S.A. Under Review with Negative Implications
-
Materna Medical Completes First Close of Series B2 Financing Round

